The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Subscribe To Our Newsletter & Stay Updated
